taurodeoxycholic acid
Modify Date: 2024-01-02 10:33:11
taurodeoxycholic acid structure
|
Common Name | taurodeoxycholic acid | ||
|---|---|---|---|---|
| CAS Number | 516-50-7 | Molecular Weight | 499.70400 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C26H45NO6S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of taurodeoxycholic acidTaurodeoxycholic acid, a bile acid, stabilizes the mitochondrial membrane, decreases free radical formation. Taurodeoxycholic acid inhibits apoptosis by blocking a calcium-mediated apoptotic pathway as well as caspase-12 activation. Taurodeoxycholic acid exhibits neuroprotective effect in 3-nitropropionic acid induced mouse model or genetic mouse model of Huntington's disease (HD)[1][2][3][4]. |
| Name | taurodeoxycholic acid |
|---|---|
| Synonym | More Synonyms |
| Description | Taurodeoxycholic acid, a bile acid, stabilizes the mitochondrial membrane, decreases free radical formation. Taurodeoxycholic acid inhibits apoptosis by blocking a calcium-mediated apoptotic pathway as well as caspase-12 activation. Taurodeoxycholic acid exhibits neuroprotective effect in 3-nitropropionic acid induced mouse model or genetic mouse model of Huntington's disease (HD)[1][2][3][4]. |
|---|---|
| Related Catalog | |
| Target |
Microbial Metabolite |
| In Vitro | Taurodeoxycholic acid (50 μM，100 μM；4 h) 增加原代人肝细胞中寡核体 DNA 切割和细胞核凋亡[1]。 Taurodeoxycholic acid (400 μM；18-24 h) 在人肝来源的 Huh7 细胞中增加 DNA 碎片和 PARP 切割，诱导凋亡[2]。 |
| In Vivo | Taurodeoxycholic acid (50 mg/kg；腹腔注射；每天 1 次，共 34 天) 预防亨廷顿舞蹈病 (HD) 大鼠模型的神经病理和相关的行为缺陷[3]。 Taurodeoxycholic acid (500 mg/kg；皮下注射；每 3 天 1 次，共 7 周) 导致 R6/2 转基因 HD 小鼠纹状体神经病理的显著降低[4]。 Animal Model: Huntington's disease model in mouse[3] Dosage: 50 mg/kg Administration: Intraperitoneal injection; once daliy for 34 d, injected 3-NP at 6 hr after Taurodeoxycholic acid treatment Result: Reduced striatal atrophy, decreased striatal apoptosis, as well as fewer and smaller size ubiquitinated neuronal intranuclear huntingtin inclusions. Significantly improved locomotor and sensorimotor deficits. |
| References |
| Molecular Formula | C26H45NO6S |
|---|---|
| Molecular Weight | 499.70400 |
| Exact Mass | 499.29700 |
| PSA | 132.31000 |
| LogP | 4.86900 |
|
~%
taurodeoxycholi... CAS#:516-50-7 |
| Literature: Cortese Journal of the American Chemical Society, 1937 , vol. 59, p. 2532 Full Text View citing articles Show Details Wieland Hoppe-Seyler's Zeitschrift fuer Physiologische Chemie, 1919 , vol. 106, p. 181,185 |
|
~%
taurodeoxycholi... CAS#:516-50-7 |
| Literature: Cortese; Bashour Journal of Biological Chemistry, 1937 , vol. 119, p. 177,180 |
|
~%
taurodeoxycholi... CAS#:516-50-7 |
| Literature: Norman Arkiv foer Kemi, 1956 , vol. 8, p. 331,338 |
| Precursor 3 | |
|---|---|
| DownStream 0 | |
| taurochenodeoxycholic acid |
| Deoxycholyltaurine |
| 2-[4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]ethanesulfonic acid |
| Tudcabil |
| Taurodeoxychloic Acid |
| [3H]-Deoxycholyltaurine |
| Taurodesoxycholic Acid |
| Deoxytaurocholic Acid |
| N-(3a,12a-Dihydroxy-5-cholan-24-oyl)taurine |
| 2-[[(3a,5,12)-3,12-Dihydroxy-24-oxocholan-24-yl]amino]ethanesulfonic Acid |